A- A A+

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort.

Lancet. 2019 Feb 11. pii: S0140-6736(18)32111-1. doi: 10.1016/S0140-6736(18)32111-1. 



Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs

Ellen Childs, Sabrina A. Assoumou, Katie B. Biello, Dea L. Biancarelli, Mari-Lynn Drainoni, Alberto Edeza, Peter Salhaney, Matthew J. Mimiaga and Angela R. Bazzi

Harm Reduction Journal 2019, 16:14, doi.org/10.1186/s12954-019-0286-6


Treatment of Hepatitis C: State of the Art 2018.

Zeuzem S.

Dtsch Med Wochenschr. 2018 Dec;143(24):1784-1788. doi: 10.1055/a-0591-5916. Epub 2018 Dec 3. German. 

[Article in German; Abstract available in German from the publisher]



Screening auf Hepatitis C – Abschlussbericht des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

Auftraggeber: Gemeinsamer Bundesausschuss

Stand: 19.09.2018

ISSN: 1864-2500


Prevalence of hepatitis C virus infection among key populations in China: a systematic-review.

Liu CR, Li X, Chan PL, Hui Z, Jia JD, Wang XC, Lo YR, Walsh N.

Int J Infect Dis. 2018 Dec 4. pii: S1201-9712(18)34584-3. doi: 10.1016/j.ijid.2018.11.006. 


USA. OxyContin reformulation to curb opioid abuse led to hepatitis C surge, study finds

Reformulation of the pain medicine OxyContin in 2010 to make it more difficult to abuse directly led to a large rise in hepatitis C infections as drug abusers switched from the prescription medication to injectable heroin, according to a new RAND Corporation study. (RAND Corporation, USA, 04.02.2019)


Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.


Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.

Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, de Lope CR, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M.

J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015-7. doi: 10.1016/j.jhep.2019.01.005.



Cardiovascular disease risk in patients with hepatitis C infection: Results from two general population health surveys in Canada and the United States (2007-2017).

Badawi A, Di Giuseppe G, Arora P (2018) 

PLoS ONE 13(12): e0208839. doi.org/10.1371/journal.pone.0208839


Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model

Heffernan, Alastair et al.

The Lancet , Volume 0 , Issue 0 , Published:January 28, 2019, doi.org/10.1016/S0140-6736(18)32277-3


Increased hepatitis C virus co-infection and injection drug use in HIV-infected fishermen in Myanmar.

Ousley J, Nesbitt R, Kyaw NTT, Bermudez E, Soe KP, Anicete R, Mon PE, Le Shwe Sin Ei W, Christofani S, Fernandez M, Ciglenecki I.

BMC Infect Dis. 2018 Dec 14;18(1):657. doi: 10.1186/s12879-018-3558-y.


Weltweite Elimination von Hepatitis C erfordert stärkere Anstrengungen

London – Die Entwicklung von direkt wirkenden antiviralen Substanzen (DAA), die eine Hepatitis-C-Infektion innerhalb von wenigen Wochen kurieren können, machen die weltweite Elimination der Hepatitis C möglich. Das ehrgeizige Ziel der Weltgesund­heitsorganisation (WHO) lässt sich laut Berechnungen im Lancet (2019; doi: 10.1016/S0140-6736(18)32277-3) jedoch nur erreichen, wenn bestimmte Bedingungen erfüllt sind. (aerzteblatt.de, 31.01.2019)


Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.

Butler K, Larney S, Day CA, Burns L.

Drug Alcohol Rev. 2018 Dec 12. doi: 10.1111/dar.12883. 



Emergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virus

Andrew McAuley, Alan Yeung, Avril Taylor, Sharon J.Hutchinson, David J.Goldberg, Alison Munro

International Journal of Drug Policy, Volume 66, April 2019, Pages 30-37, doi.org/10.1016/j.drugpo.2019.01.008


Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.

Radley A, de Bruin M, Inglis SK, Donnan PT, Dillon JF.

BMJ Open. 2018 Dec 14;8(12):e021443. doi: 10.1136/bmjopen-2017-021443.


Understanding HIV and hepatitis C virus risk among incarcerated young men with histories of injecting drug use

Walker, Shelley et al.

The Lancet Infectious Diseases , Volume 19 , Issue 2 , 130 - 131 


Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.

Gallach M, Vergara M, da Costa JP, Miquel M, Casas M, Sanchez-Delgado J, et al. (2018) 

PLoS ONE 13(12): e0208112. doi.org/10.1371/journal.pone.0208112


Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND.

Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30057-5. doi: 10.1053/j.gastro.2019.01.027. 



Hepatitis C Prevalence and Management Among Patients Receiving Opioid Substitution Treatment in General Practice in Ireland: Baseline Data from a Feasibility Study.

Murtagh R, Swan D, O'Connor E, McCombe G, Lambert JS, Avramovic G, Cullen W.

Interact J Med Res. 2018 Dec 19;7(2):e10313. doi: 10.2196/10313.


Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.

Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A.

J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30024-8. doi: 10.1016/j.jhep.2019.01.012.



Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration.

Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W.

Health Justice. 2018 Dec 19;6(1):23. doi: 10.1186/s40352-018-0081-6.


Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs.

Sweeney S, Ward Z, Platt L, Guinness L, Hickman M, Hope V, Maher L, Iversen J, Hutchinson SJ, Smith J, Ayres R, Hainey I, Vickerman P.

Addiction. 2019 Jan 23. doi: 10.1111/add.14519.


Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents.

Gualerzi A, Bellan M, Smirne C, Tran Minh M, Rigamonti C, Burlone ME, et al. (2018) 

PLoS ONE 13(12): e0209216. doi.org/10.1371/journal.pone.0209216


Trends in cause-specific mortality in HIV-Hepatitis C co-infection following hepatitis C treatment scale-up.

Kronfli N, Bhatnagar SR, Hull MW, Moodie EEM, Cox J, Walmsley S, Gill J, Cooper C, Martel-Laferriere V, Pick N, Klein MB; Canadian Co-Infection Cohort Investigators.

AIDS. 2019 Jan 12. doi: 10.1097/QAD.0000000000002156. 

Abstract -> open access -> pdf


Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X.

Therap Adv Gastroenterol. 2018 Dec 2;11:1756284818812358. doi: 10.1177/1756284818812358. Review


Mechanismus des Leberversagens bei Hepatitis

München – Eine Virushepatitis kann bekanntlich zum Zusammenbruch der Leberfunktion führen. Wissenschaftler der Technischen Universität München (TUM) haben jetzt den Pathomechanismus beim Leberversagen beschrieben und im Tiermodell einen Wirkstoff identifiziert, der diese tödlichen Prozesse verhindert. (aerzteblatt.de, 02.01.2018)


Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy.

Villani R, Vendemiale G, Serviddio G.

Int J Mol Sci. 2018 Dec 22;20(1). pii: E49. doi: 10.3390/ijms20010049. Review.


Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.

Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, et al. (2018)

PLoS ONE 13(6): e0197544. doi.org/10.1371/journal.pone.0197544


Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?

Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. (2018) 

PLoS ONE 13(12): e0209374. doi.org/10.1371/journal.pone.0209374


Development, validation, and potential applications of the hepatitis C virus injection-risk knowledge scale (HCV-IRKS) among young opioid users in New York City.

Quinn K, Fong C, Guarino H, Mateu-Gelabert P.

Drug Alcohol Depend. 2019 Jan 1;194:453-459. doi: 10.1016/j.drugalcdep.2018.11.010.